entete

Philippe Pibarot DVM, PhD, FACC, FAHA, FASE, FESC

Professor, Faculty of medicine, Laval University
Director, Canadian Research Chair in Valvular Heart Disease

Principal investigator
Pulmonary Hypertension Research Group 
Centre de recherche de l’Institut universitaire de cardiologie et pneumologie de Québec (CRIUCPQ)
2725, chemin Sainte-Foy, Québec (Québec), Canada, G1V 4G5

Philippe Pibarot was born in Toulon, France in 1964. He obtained a doctorate in veterinary medicine (DVM) in 1987 at the University Claude Bernard in Lyon, France. He obtained his PhD degree in biomedical sciences from the University of Montreal in April 1995.

He is currently full professor at the Department of Medicine of Laval University, and director of the Research Group in Valvular Heart Diseases at the Québec Heart & Lung Institute. He holds the Canada Research Chair in Valvular Heart Disease. The objective of his research program is to develop and validate novel approaches to improve the diagnosis, prevention, and treatment of valvular heart diseases. He is currently the principal investigator of 3 multicenter studies (TOPAS, PROGRESSA, PROGRAM) funded by Canadian Institutes of Health Research and the Heart and Stroke Foundation of Québec. He has published more than 200 articles and presented 190 invited conferences in the course of his career. He received the James Hogg Award from the Institute of Circulatory and Respiratory Health (2006), the André Dupont Award from the Club de Recherches Cliniques du Québec (2006), the Preventive Cardiology Award of Excellence from the Heart and Stroke Foundation of Québec and 4th International Conference on Preventive Cardiology (2007), the Annual Achievement Award of the Canadian Society of Echocardiography (2010), and the Research Achievement Award, Canadian Cardiovascular Society (2010). He was the chair of the Scientific Program Committee of the Canadian Cardiovascular Congress (2010-2011) and he has been elected as member of the nucleus of the Working Group in Valvular heart Diseases of the European Society of Cardiology.

Grants :

  • Metabolic determinants of the progression of aortic stenosis – PROGRESSA Study Phase-II. CIHR; 2011 - 2016; Investigateur Principal.
  • Multicenter prospective study of low flow aortic stenosis – TOPAS Study Phase II. CIHR; 2007-2012; Investigateur Principal.
  • Determinants of the progression and outcome of mitral regurgitation. PROGRAM Study Phase I. CIHR; 2010-2015; Investigateur Principal.
  • Implication of atherosclerotic pathways and metabolic risk factors in the structural deterioration of bioprosthetic heart valves. CIHR; 2008-2013 Co-investigateur.
  • Identification of susceptibility genes for calcific aortic valve stenosis. CIHR; 2010-2014 Co-investigateur.
  • Prospective association studies for mass and function of cardiac left ventricle and plasma natriuretic peptides. 2007-2012 Co-investigateur. 
  • Echocardiographic assessment of global and regional left ventricular function using an original modality of coupled wall-fluid dynamic mapping.CIHR. 2010-2015 Co-investigateur.
  • Rubidium PET - An Alternative Radiopharmaceutical for Myocardial Imaging (Rb-ARMI). CIHR; 2010-2015 (Co-investigateur).
  • Canada Research  in Valvular Heart Diseases. CIHR; 2008-2013 (Investigateur principal).

Awards:

  • prix de la ConfĂ©rence Feigenbaum, 23ième congrès de l’American Society of Echocardiography (2012)
  • James Hogg Award from the Institute of Circulatory and Respiratory Health (2006),
  • AndrĂ© Dupont Award from the Club de Recherches Cliniques du QuĂ©bec (2006),
  • The Preventive Cardiology Award of Excellence from the Heart and Stroke Foundation of QuĂ©bec and 4th International Conference on Preventive Cardiology (2007),
  • The Annual Achievement Award of the Canadian Society of Echocardiography (2010),
  • The Research Achievement Award, Canadian Cardiovascular Society (2010).
© 2012 Université Laval. Tous droits réservés